Literature DB >> 32607629

Machine learning for the identification of clinically significant prostate cancer on MRI: a meta-analysis.

Renato Cuocolo1, Maria Brunella Cipullo1, Arnaldo Stanzione2, Valeria Romeo1, Roberta Green1, Valeria Cantoni1, Andrea Ponsiglione1, Lorenzo Ugga1, Massimo Imbriaco1.   

Abstract

OBJECTIVES: The aim of this study was to systematically review the literature and perform a meta-analysis of machine learning (ML) diagnostic accuracy studies focused on clinically significant prostate cancer (csPCa) identification on MRI.
METHODS: Multiple medical databases were systematically searched for studies on ML applications in csPCa identification up to July 31, 2019. Two reviewers screened all papers independently for eligibility. The area under the receiver operating characteristic curves (AUC) was pooled to quantify predictive accuracy. A random-effects model estimated overall effect size while statistical heterogeneity was assessed with the I2 value. A funnel plot was used to investigate publication bias. Subgroup analyses were performed based on reference standard (biopsy or radical prostatectomy) and ML type (deep and non-deep).
RESULTS: After the final revision, 12 studies were included in the analysis. Statistical heterogeneity was high both in overall and in subgroup analyses. The overall pooled AUC for ML in csPCa identification was 0.86, with 0.81-0.91 95% confidence intervals (95%CI). The biopsy subgroup (n = 9) had a pooled AUC of 0.85 (95%CI = 0.79-0.91) while the radical prostatectomy one (n = 3) of 0.88 (95%CI = 0.76-0.99). Deep learning ML (n = 4) had a 0.78 AUC (95%CI = 0.69-0.86) while the remaining 8 had AUC = 0.90 (95%CI = 0.85-0.94).
CONCLUSIONS: ML pipelines using prostate MRI to identify csPCa showed good accuracy and should be further investigated, possibly with better standardisation in design and reporting of results. KEY POINTS: • Overall pooled AUC was 0.86 with 0.81-0.91 95% confidence intervals. • In the reference standard subgroup analysis, algorithm accuracy was similar with pooled AUCs of 0.85 (0.79-0.91 95% confidence intervals) and 0.88 (0.76-0.99 95% confidence intervals) for studies employing biopsies and radical prostatectomy, respectively. • Deep learning pipelines performed worse (AUC = 0.78, 0.69-0.86 95% confidence intervals) than other approaches (AUC = 0.90, 0.85-0.94 95% confidence intervals).

Entities:  

Keywords:  Machine learning; Magnetic resonance imaging; Meta-analysis; Prostatic neoplasms

Year:  2020        PMID: 32607629     DOI: 10.1007/s00330-020-07027-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  16 in total

Review 1.  Deep learning-based artificial intelligence applications in prostate MRI: brief summary.

Authors:  Baris Turkbey; Masoom A Haider
Journal:  Br J Radiol       Date:  2021-12-03       Impact factor: 3.039

Review 2.  Quality in MR reporting (include improvements in acquisition using AI).

Authors:  Liang Wang; Daniel J Margolis; Min Chen; Xinming Zhao; Qiubai Li; Zhenghan Yang; Jie Tian; Zhenchang Wang
Journal:  Br J Radiol       Date:  2022-02-04       Impact factor: 3.039

3.  Meningioma MRI radiomics and machine learning: systematic review, quality score assessment, and meta-analysis.

Authors:  Lorenzo Ugga; Teresa Perillo; Renato Cuocolo; Arnaldo Stanzione; Valeria Romeo; Roberta Green; Valeria Cantoni; Arturo Brunetti
Journal:  Neuroradiology       Date:  2021-03-02       Impact factor: 2.804

4.  Machine and Deep Learning Prediction Of Prostate Cancer Aggressiveness Using Multiparametric MRI.

Authors:  Elena Bertelli; Laura Mercatelli; Chiara Marzi; Eva Pachetti; Michela Baccini; Andrea Barucci; Sara Colantonio; Luca Gherardini; Lorenzo Lattavo; Maria Antonietta Pascali; Simone Agostini; Vittorio Miele
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

5.  Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature.

Authors:  Li Zhang; Xia Zhe; Min Tang; Jing Zhang; Jialiang Ren; Xiaoling Zhang; Longchao Li
Journal:  Contrast Media Mol Imaging       Date:  2021-12-23       Impact factor: 3.161

6.  Diagnostic Accuracy of Artificial Intelligence Based on Imaging Data for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jian Zhang; Shenglan Huang; Yongkang Xu; Jianbing Wu
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

Review 7.  Comparative performance of fully-automated and semi-automated artificial intelligence methods for the detection of clinically significant prostate cancer on MRI: a systematic review.

Authors:  Michael Roberts; Leonardo Rundo; Nikita Sushentsev; Nadia Moreira Da Silva; Michael Yeung; Tristan Barrett; Evis Sala
Journal:  Insights Imaging       Date:  2022-03-28

Review 8.  State of the Art in Artificial Intelligence and Radiomics in Hepatocellular Carcinoma.

Authors:  Anna Castaldo; Davide Raffaele De Lucia; Giuseppe Pontillo; Marco Gatti; Sirio Cocozza; Lorenzo Ugga; Renato Cuocolo
Journal:  Diagnostics (Basel)       Date:  2021-06-30

9.  ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging.

Authors:  Tobias Penzkofer; Anwar R Padhani; Baris Turkbey; Masoom A Haider; Henkjan Huisman; Jochen Walz; Georg Salomon; Ivo G Schoots; Jonathan Richenberg; Geert Villeirs; Valeria Panebianco; Olivier Rouviere; Vibeke Berg Logager; Jelle Barentsz
Journal:  Eur Radiol       Date:  2021-05-15       Impact factor: 5.315

10.  MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study.

Authors:  Renato Cuocolo; Arnaldo Stanzione; Riccardo Faletti; Marco Gatti; Giorgio Calleris; Alberto Fornari; Francesco Gentile; Aurelio Motta; Serena Dell'Aversana; Massimiliano Creta; Nicola Longo; Paolo Gontero; Stefano Cirillo; Paolo Fonio; Massimo Imbriaco
Journal:  Eur Radiol       Date:  2021-04-01       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.